Archives
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Serum soluble sCD is a
2023-07-29
Serum soluble sCD21 is a shedding product from the ectodomain of membrane CD21 after B cell activation (Masilamani et al., 2003, Masilamani et al., 2004a, Masilamani et al., 2004b, Grottenthaler et al., 2006, Hoefer et al., 2008), which resembles the ligand-binding capacity of intact CD21 (Wu et al.
-
Overexpression of SMAD and SMAD strongly enhanced
2023-07-29
Overexpression of SMAD3 and SMAD4 strongly enhanced luciferase activity of the new pN10 reporter gene construct which was further reinforced by addition of TGFβ. Serial mutations of SBE-1 and SBE-2 led to a slight loss in 5-LO promoter inducibility. The data demonstrate that the two SBEs within the
-
Introduction hydroxytryptamine HT is found
2023-07-29
Introduction 5-hydroxytryptamine (5-HT) is found throughout the body and influences smooth muscle activity in various tissues including the intestine, vasculature and urinary nf-κb inhibitor (Kim and Camilleri, 2000, Klarskov and Horby-Petersen, 1986, Mohammad-Zadeh et al., 2008). The current class
-
Steroidal CYP inhibitors can further be classified based on
2023-07-29
Steroidal CYP17 inhibitors can further be classified based on their mode of action, namely as mechanism-based inhibitors and type I and type II competitive inhibitors [129]. Recent studies investigated other biological targets than CYP17, and some new compounds have shown interesting dual activity a
-
pla2 inhibitor The exact etiology of BPH is not completely u
2023-07-29
The exact etiology of BPH is not completely understood, however this pathology has been associated with elevated pla2 inhibitor levels of the androgen DHT (10). Thus, a valuable strategy in BHP treatment is the reduction of DHT (10) levels, by inhibiting its biosynthetic production [6], [8]. An impo
-
DGAT-1 inhibitor If the lack of specificity and the
2023-07-29
If the lack of specificity and the high pleiotropy may represent a problem in view of the potential chemotherapeutic features of autophagy-inducing agents, it DGAT-1 inhibitor may switch into an advantage in the case of chemopreventive strategies. In fact, as non-pharmacologic interventions such as
-
The evidence points toward a
2023-07-29
The evidence points toward a role for 12/15-LO activity in WAT in modulating chronic local inflammation and subsequent systemic metabolic decline in the obese state. However, little is known as to the role of 12- and 15-LOs in BAT. Indeed, in addition to WAT, platelet- and leukocyte-type 12-LO are e
-
Exposure to cisplatin with ATR
2023-07-29
Exposure to cisplatin with ATR inhibitor resulted in an increase in cisplatin-DNA adducts, especially in cells with ATM deficiency. This finding indicates that suppressing ATR-Chk1 signaling with VE-822 enhances cisplatin activity by enabling the drug to form DNA adducts. Therefore, VE-822 may incre
-
Several studies have demonstrated that depletion of function
2023-07-29
Several studies have demonstrated that depletion of functional ATR increases the sensitivity of cancer cells to oncogene-induced replication stress thereby hindering tumour growth and inducing extensive cell death (Gilad et al., 2010, Murga et al., 2011, Schoppy et al., 2012). Importantly, Schoppy e
-
br Materials and methods br Results
2023-07-29
Materials and methods Results Discussion Despite the relative complexity of immunotherapy, such treatment may have an important role, in conjunction with other therapies in the treatment of cancer refractory to conventional treatments alone. Clinical studies have recently shown that adding
-
CHIR-99021 br Acknowledgements This work was supported
2023-07-29
Acknowledgements This work was supported, in part, by NIH grant R01-GM071760. Introduction The MADS box genes encode a eukaryotic family of transcriptional regulators involved in diverse and important biological functions. This class of proteins has been identified in yeasts, plants, insects,
-
Electron paramagnetic resonance studies of mixtures
2023-07-29
Electron paramagnetic resonance studies of mixtures of Aβ1–40 and Aβ1–42 suggest that interlaced fibrils might also form [40] where Aβ1–40 and Aβ1–42 is found within the same fibril. Considering the Aβ fold rather than the sequence, these observations imply two mechanisms that might lower the total
-
Critically we found that pre treatment with
2023-07-29
Critically we found that pre-treatment with Aβ monomer preparations prevented the Aβ oligomer-induced aggregation of PrPC. These preparations contain a mixture of Aβ species and consequently it was not possible to identify the precise form of Aβ that is responsible for this effect. It is possible th
-
Although only Leu CysAP IRAP Herbest et al Keller and
2023-07-29
Although only Leu/CysAP (IRAP) (Herbest et al., 1997, Keller, 2004) and DPPIV (Alponti and Silveira, 2010, Kirino et al., 2009) had been identified and studied in adipocytes, our kinetic analysis suggested the highest physiological significance for AspAP (highest affinity) and APM and PSA (highest e
-
Imatinib was first approved for the treatment of
2023-07-29
Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h
16251 records 308/1084 page Previous Next First page 上5页 306307308309310 下5页 Last page